Publications

Zanidatamab

Categories
Search
Zanidatamab
June 4, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study
Zanidatamab
April 10, 2021
AACR
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abraham et al.
Zanidatamab
December 8, 2021
SABCS
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Bedard et al.
Zanidatamab
September 15, 2021
ESMO
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA)
Ku et al.
Zanidatamab
December 8, 2021
SABCS
Zanidatamab in Combination with Evorpacept in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204)
Hurvitz et al.
Zanidatamab
April 10, 2021
AACR
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Weisser et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
Pant et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
November 22, 2019
ESMO Asia
Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor
Oh et al.